Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabozantinib - Exelixis/Ipsen

Drug Profile

Cabozantinib - Exelixis/Ipsen

Alternative Names: BMS-907351; CABOMETYX; Cabometyx; Cabozantinib s-malate; Cometriq; XL-184

Latest Information Update: 14 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Centre Francois Baclesse; Dana-Farber Cancer Institute; Duke University Medical Center; Emory University; Exelixis; Ipsen; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); Roche; Swedish Orphan Biovitrum; Takeda; University of California at Irvine; University of Kentucky
  • Class Amides; Anilides; Antineoplastics; Cyclopropanes; Fluorine compounds; Quinolines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c ret inhibitors; Proto-oncogene protein c-met inhibitors; TIE 2 receptor antagonists; TrkB receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer; Renal cell carcinoma; Thyroid cancer
  • Phase III Neuroendocrine tumours; Non-small cell lung cancer; Prostate cancer
  • Phase II Adenocarcinoma; Adrenocortical carcinoma; Bone metastases; Brain metastases; Breast cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Gastrointestinal cancer; Head and neck cancer; Malignant fibrous histiocytoma; Malignant melanoma; Merkel cell carcinoma; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Phaeochromocytoma; Urogenital cancer; Uveal melanoma
  • Phase I/II Multiple myeloma; Solid tumours
  • No development reported Acute myeloid leukaemia; Astrocytoma; Cancer; Colorectal cancer; Glioblastoma

Most Recent Events

  • 06 Feb 2024 Ipsen announces intention to file regulatory submission for Castrate-resistant prostate cancer(Combination therapy, Hormone-refractory, Metaststic disease, Second-line therapy or greater) in Japan in 2024 (Takeda pipeline, November 2022)
  • 25 Jan 2024 Updated efficacy data from the phase III CheckMate 9ER trial in Renal cell carcinoma presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
  • 25 Jan 2024 Efficacy and adverse events data from a phase I/Ib trial in Urogenital cancer were released by Exelixis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top